 | • レポートコード：MRC2209A027 • 出版社/出版日：Persistence Market Research / 2022年5月 • レポート形態：英文、PDF、177ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社発行の本調査レポートでは、世界のRNA (メッセンジャーRNA) 治療薬・ワクチン市場について広く調査・分析し、エグゼクティブサマリー、市場概要、市場機会分析、地域・国別国内総生産、市場背景、競争分析、企業情報、製品別（ワークステーション、試薬・消耗品、キット（RNAサンプル調製用、DNAサンプル調製用））分析、用途別（研究用、診断検査用、臨床検査用）分析、エンドユーザー別（診断センター、病院、学術・研究機関、法医学研究所、CRO（医薬品開発業務受託機関））分析、地域別分析（北米、中南米、ヨーロッパ、アジア太平洋、中東/アフリカ）、市場構造分析、競争分析、仮定、調査手法などの項目を掲載しております。なお、主要企業として、Alnylam Pharmaceuticals, Inc.、Arbutus Biopharma Corp.、Arrowhead Pharmaceuticals, Inc.、BioNTech AG、CureVac AG、Dicerna Pharmaceuticals, Inc.、Regulus Therapeutics, Inc.、Marina Biotech, Inc.、miRagen Therapeutics、Moderna Therapeutics, Inc.、Quark Pharmaceuticals, Inc.、Santaris Pharma A/S (A Roche Company)などが含まれています。 ・エグゼクティブサマリー ・市場概要 ・市場機会分析 ・地域・国別国内総生産 ・市場背景 ・競争分析 ・企業情報 ・世界のRNA (メッセンジャーRNA) 治療薬・ワクチン市場規模：製品別 - RNA (メッセンジャーRNA) 治療薬・ワクチンワークステーションにおける市場規模 - RNA (メッセンジャーRNA) 治療薬・ワクチン試薬・消耗品における市場規模 - キット（RNAサンプル調製用、DNAサンプル調製用）における市場規模 ・世界のRNA (メッセンジャーRNA) 治療薬・ワクチン市場規模：用途別 - 研究用RNA (メッセンジャーRNA) 治療薬・ワクチンにおける市場規模 - 診断検査用RNA (メッセンジャーRNA) 治療薬・ワクチンにおける市場規模 - 臨床検査用RNA (メッセンジャーRNA) 治療薬・ワクチンにおける市場規模 ・世界のRNA (メッセンジャーRNA) 治療薬・ワクチン市場規模：エンドユーザー別 - 診断センターにおける市場規模 - 病院における市場規模 - 学術・研究機関における市場規模 - 法医学研究所における市場規模 - CRO（医薬品開発業務受託機関）における市場規模 ・世界のRNA (メッセンジャーRNA) 治療薬・ワクチン市場規模：地域別 - 北米のRNA (メッセンジャーRNA) 治療薬・ワクチン市場規模 - ヨーロッパのRNA (メッセンジャーRNA) 治療薬・ワクチン市場規模 - アジア太平洋のRNA (メッセンジャーRNA) 治療薬・ワクチン市場規模 - 中東/アフリカのRNA (メッセンジャーRNA) 治療薬・ワクチン市場規模 ・製品機会評価 ・仮定 ・調査手法 |
RNA-Based Therapeutics and Vaccines Market Analysis 2022-2028
A recent market study published by Persistence Market Research (PMR) on the RNA-Based Therapeutics and Vaccines Market including global industry analysis for 2013-2021 & opportunity assessment for 2022-2028, delivers a comprehensive assessment of the most important market dynamics. After conducting a thorough research on the historical as well as current growth parameters of the market, growth prospects are obtained with utmost precision.
RNA-Based Therapeutics and Vaccines Market: Segmentation
The global RNA-Based Therapeutics and Vaccines Market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Product Type
Workstations
Reagents and Consumables
Kits (RNA sample preparation and DNA sample preparation)
Application
Research Applications
Diagnostic Testing
Clinical Testing
End User
Diagnostic Centers
Hospitals
Academic & Research Institutes
Forensic Science Laboratories
CROs (Contract Research Organizations)
Region
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa (MEA)
Key Questions Answered in Report
The research study offers inclusive insights about the growth of the market in the most comprehensive manner. Key insights offered in the report answer some of the most salient questions that assist stakeholders in gauging all the emerging possibilities.
What are the key trends that are continuously shaping market growth?
Which are the prominent regions that offer plentiful opportunities for players in the market?
How has the outbreak of COVID-19 affected the market and what would the trend be like during the forecast period?
What are the differential strategies adopted by key players to hold a significant share in the RNA-Based Therapeutics and Vaccines industry?
Research Methodology
A unique and promising research methodology forms the base of the market report for the forecast period. This report has been prepared after comprehensive analysis of market events, and riveting insights have been compiled meticulously.
The research methodology is a two-step process comprising primary and secondary research. Key stakeholders, including suppliers, service providers, and experts of several designations, including executive vice presidents, directors, technical advisors, GM marketing professionals, and sales professionals have been interviewed. Secondary sources referred to obtain information include investor presentations of manufacturers, World Bank, IMF, and other credible sources.
The research report includes a competitive landscape that provides a dashboard view of the key competitors operating in the market. Some of the market players included in this section are Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corp., Arrowhead Pharmaceuticals, Inc., BioNTech AG, CureVac AG, Dicerna Pharmaceuticals, Inc., and Regulus Therapeutics, Inc., among others.
レポート目次1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. PMR Analysis and Recommendations
2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy
3. RNA-based Therapeutics and Vaccines Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. Market Background
4.1. Regulatory Scenario
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity Analysis
4.3. Pipeline Assessment
5. Gross Domestic Product by Region & Country, 2006 – 2021
6. North America RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028
6.1. Introduction
6.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2022-2028
6.2.1. U.S.
6.2.2. Canada
6.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028
6.3.1. RNA-based Therapeutics
6.3.1.1. siRNA
6.3.1.2. miRNA
6.3.2. RNA-based Vaccines
6.3.2.1. mRNA
6.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028
6.4.1. Oncology
6.4.2. Immunology
6.4.3. Ophthalmology
6.4.4. Cardiovascular Diseases
6.4.5. Infectious Diseases
6.4.6. Genetic Diseases
6.4.7. Others
6.5. Drivers and Restraints – Impact Analysis
7. Latin America RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028
7.1. Introduction
7.2. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028
7.2.1. RNA-based Therapeutics
7.2.1.1. siRNA
7.2.1.2. miRNA
7.2.2. RNA-based Vaccines
7.2.2.1. mRNA
7.3. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028
7.3.1. Oncology
7.3.2. Immunology
7.3.3. Ophthalmology
7.3.4. Cardiovascular Diseases
7.3.5. Infectious Diseases
7.3.6. Genetic Diseases
7.3.7. Others
7.4. Drivers and Restraints – Impact Analysis
8. Europe RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028
8.1. Introduction
8.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2022-2028
8.2.1. Germany
8.2.2. U.K.
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028
8.3.1. RNA-based Therapeutics
8.3.1.1. siRNA
8.3.1.2. miRNA
8.3.2. RNA-based Vaccines
8.3.2.1. mRNA
8.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028
8.4.1. Oncology
8.4.2. Immunology
8.4.3. Ophthalmology
8.4.4. Cardiovascular Diseases
8.4.5. Infectious Diseases
8.4.6. Genetic Diseases
8.4.7. Others
8.5. Drivers and Restraints – Impact Analysis
9. Asia Pacific RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028
9.1. Introduction
9.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2022-2028
9.2.1. China
9.2.2. Japan
9.2.3. Australia & New Zealand
9.2.4. Rest of APAC
9.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028
9.3.1. RNA-based Therapeutics
9.3.1.1. siRNA
9.3.1.2. miRNA
9.3.2. RNA-based Vaccines
9.3.2.1. mRNA
9.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028
9.4.1. Oncology
9.4.2. Immunology
9.4.3. Ophthalmology
9.4.4. Cardiovascular Diseases
9.4.5. Infectious Diseases
9.4.6. Genetic Diseases
9.4.7. Others
9.5. Drivers and Restraints – Impact Analysis
10. Middle East & Africa RNA-based Therapeutics and Vaccines Opportunity Assessment 2022-2028
10.1. Introduction
10.2. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028
10.2.1. RNA-based Therapeutics
10.2.1.1. siRNA
10.2.1.2. miRNA
10.2.2. RNA-based Vaccines
10.2.2.1. mRNA
10.3. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028
10.3.1. Oncology
10.3.2. Immunology
10.3.3. Ophthalmology
10.3.4. Cardiovascular Diseases
10.3.5. Infectious Diseases
10.3.6. Genetic Diseases
10.3.7. Others
10.4. Drivers and Restraints – Impact Analysis
11. Competition Analysis
11.1. Competition Dashboard
12. Company Profiles
12.1. Company Deep Dive
12.1.1. Alnylam Pharmaceuticals, Inc.
12.1.2. Arbutus Biopharma Corp.
12.1.3. Arrowhead Pharmaceuticals, Inc.
12.1.4. BioNTech AG
12.1.5. CureVac AG
12.1.6. Dicerna Pharmaceuticals, Inc.
12.1.7. Regulus Therapeutics, Inc.
12.1.8. Marina Biotech, Inc.
12.1.9. miRagen Therapeutics
12.1.10. Moderna Therapeutics, Inc.
12.1.11. Quark Pharmaceuticals, Inc.
12.1.12. Santaris Pharma A/S (A Roche Company)
12.1.13. Sylentis S.A.
13. Global RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028, By Region
13.1. Introduction/Key Findings
13.2. Market Size (US$ Mn) Opportunity Assessment By Region, 2022-2028
13.2.1. North America
13.2.2. Latin America
13.2.3. Europe
13.2.4. Asia Pacific Excluding China
13.2.5. Middle East & Africa
13.2.6. China
13.3. Market Attractiveness Analysis By Region
14. Global Product Opportunity Assessment 2022-2028, By Product Type
14.1. Introduction/Key Findings
14.2. Market Size (US$ Mn) and Volume Opportunity Assessment By Product Type, 2022-2028
14.2.1. RNA-based Therapeutics
14.2.1.1. siRNA
14.2.1.2. miRNA
14.2.2. RNA-based Vaccines
14.2.2.1. mRNA
14.3. Market Attractiveness Analysis By Product Type
15. Global Product Opportunity Assessment 2022-2028, By Indication Type
15.1. Introduction/Key Findings
15.2. Market Size (US$ Mn) and Volume Opportunity Assessment By Indication Type, 2022-2028
15.2.1. Oncology
15.2.2. Immunology
15.2.3. Ophthalmology
15.2.4. Cardiovascular Diseases
15.2.5. Infectious Diseases
15.2.6. Genetic Diseases
15.2.7. Others
15.3. Market Attractiveness Analysis By Indication
16. Global Product Opportunity Assessment 2022-2028
16.1. Market Opportunity Assessment By All Segment
16.2. Absolute $ Opportunity
17. Assumption & Acronyms Used
18. Research Methodology
Table 1: Expenditure on Health, (% of GDP), by Country, 2013 - 2021Table 2: Expenditure on Health, (% of GDP), by Country, 2013 - 2021
Table 3: North America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Country
Table 4: North America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Product Type
Table 5: North America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Indication
Table 6: Latin America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Product Type
Table 7: Latin America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Indication
Table 8: Europe RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Country
Table 9: Europe RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Product Type
Table 10: Europe RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Indication
Table 11: Asia Pacific RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Country
Table 12: Asia Pacific RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Product Type
Table 13: Asia Pacific RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Indication
Table 14: Middle East & Africa RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment 2022-2028, By Product Type
Table 15: Middle East & Africa RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment 2022-2028, By Indication
Table 16: Competitive Scenario for Hereditary ATTR Amyloidosis (Patisiran (ALN-TTR02))
Table 17: Competitive Scenario for Hemophilia A Fitusiran (ALN-AT3SC)
Table 18: Competitive Scenario for Hypercholesterolemia (Inclisiran)
Table 19: Global RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment 2022-2028, By Region
Table 20: Global RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Product Type
Table 21: Global RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment 2022-2028, By Indication